A Double-blind, Placebo-controlled Investigation of the Effects of Passiflora incarnata (Passionflower) Herbal Tea on Subjective Sleep Quality

School of Psychology and Psychiatry, Monash University, Clayton, Victoria, Australia.
Phytotherapy Research (Impact Factor: 2.66). 08/2011; 25(8):1153-9. DOI: 10.1002/ptr.3400
Source: PubMed


Passiflora incarnata is a traditional herbal sedative, anxiolytic and a popular sleep aid used for the treatment of sleep disturbance. Several controlled experiments have demonstrated enhanced sleep in laboratory animals, but clinical trials in humans are lacking. The aim of the present study was to investigate the efficacy of Passiflora incarnata herbal tea on human sleep, as measured using sleep diaries validated by polysomnography (PSG). This study featured a double-blind, placebo-controlled, repeated-measures design with a counterbalanced order of treatments (passionflower vs placebo tea), separated by a 1 week 'washout' period. Forty-one participants (18-35 years) were exposed to each treatment for a week, whereby they consumed a cup of the tea and filled out a sleep diary for 7 days, and completed Spielberger's state-trait anxiety inventory on the seventh morning. Ten participants also underwent overnight PSG on the last night of each treatment period. Of six sleep-diary measures analysed, sleep quality showed a significantly better rating for passionflower compared with placebo (t(40) = 2.70, p < 0.01). These initial findings suggest that the consumption of a low dose of Passiflora incarnata, in the form of tea, yields short-term subjective sleep benefits for healthy adults with mild fluctuations in sleep quality.

Download full-text


Available from: Russell Conduit, Dec 03, 2014
  • Source
    • "Although the pharmacological effects of Passiflora species have been investigated (Appel et al., 2011; Ngan and Conduit, 2011), the antihypertensive activity of these species has been evaluated only in peel extracts from Passiflora edulis (Ichimura et al., 2006; Zibadi et al., 2007). The mechanisms involved in this effect have not been clearly elucidated. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Various species of the genus Passiflora have been extensively used in traditional medicine as sedatives, anxiolytics, diuretics and analgesics. In the present study, after the identification and quantification of phytochemical compounds from yellow passion fruit pulp by liquid chromatography-photodiode array-mass spectrometry (HPLC-PDA-MS/MS), its antihypertensive effect was investigated on spontaneously hypertensive rats. Additionally, the renal function, evaluated by kidney/body weight, serum creatinine, proteinuria, urinary flow, reduced glutathione (GSH) levels and thiobarbituric acid-reactive substances (TBARS) and mutagenicity in bone marrow cells were assessed to evaluate the safety of passion fruit consumption. Yellow passion fruit pulp (5, 6 or 8 g/kg b.w.) was administered by gavage once a day for 5 consecutive days. HLPC-PDA-MS/MS analysis revealed that yellow passion fruit pulp contains phenolic compounds, ascorbic acid, carotenoids and flavonoids. The highest dose of passion fruit pulp significantly reduced the systolic blood pressure, increased the GSH levels and decreased TBARS. There were no changes in renal function parameters or the frequency of micronuclei in bone marrow cells. In conclusion, the antihypertensive effect of yellow passion fruit pulp, at least in part, might be due to the enhancement of the antioxidant status. The exact mechanisms responsible by this effect need further investigation. Copyright © 2013 John Wiley & Sons, Ltd.
    Phytotherapy Research 01/2014; 28(1). DOI:10.1002/ptr.4949 · 2.66 Impact Factor
    • "Passion flower has been tried for various indications in both animal and human studies, including anxiety[6] and hypertension.[7] It has also been investigated for its sedative and hypnotic activity.[8] Bioactive compounds in passion flower include alkaloids, phenols, cyanogenic compounds and glycosyl flavonoids. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To assess the efficacy and safety of NSF-3, a polyherbal sedative-hypnotic (containing standardized extracts of Valeriana officinalis, Passiflora incarnate and Humulus lupulus), in comparison to zolpidem in primary insomnia. The present study was designed as a parallel group, double- blind, randomized, controlled trial and registered with Clinical Trials Registry-India (CTRI/2011/12/002197). Patients diagnosed with primary insomnia with a perceived total sleep time of <6 hours per night and insomnia severity index >7 were included. They were treated with either NSF-3 (one tablet) or zolpidem (one 10 mg tablet) at bedtime for two weeks. Total sleep time, sleep latency and number of awakenings per night were assessed using a sleep diary. Quality of life and daytime sleepiness were evaluated by insomnia severity index and Epworth sleepiness score respectively. Vital signs, routine blood counts, liver and renal function tests, and treatment emergent adverse events were recorded for safety assessment. A total of 91 subjects were recruited, of which 39 in each group completed the study. There was significant improvement in total sleep time, sleep latency, number of nightly awakenings and insomnia severity index scores in both groups. However, no statistically significant difference was observed between the groups. Epworth sleepiness scores did not change significantly over the study period. Although 12 treatment emergent adverse events were reported with NSF-3 and 16 with zolpidem (commonest was drowsiness in both), most were mild and no serious adverse events were encountered. NSF-3 is a safe and effective short-term alternative to zolpidem for primary insomnia. It remains to be explored whether the benefits are sustained and whether there is dependence liability with this formulation upon long term use.
    Indian Journal of Pharmacology 03/2013; 45(1):34-9. DOI:10.4103/0253-7613.106432 · 0.69 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction. Among pediatric population the sleep disturbances are very common and they can cause cognitive and behavioral impairments. When insomnia is not pathologic, herbal compounds can be used avoiding the side effects of drugs. Aim. Evaluation of a new herbal compound in the treatment of sleep disturbances in a pediatric cohort. Methods. An herbal compound of Eschscholtzia californica and Passiflora incarnata (Vagostabil® Junior) was given to 20 children affected by sleep disorders for 14 consecutive days. Results. The total score of Tayside is improved (p <0.001): from 23.58 ± 5.77 (range 13 - 34) to 14.11 ± 6.72 (range 5 - 32). In particular, children appears to be less reluctant to go to sleep (p <0.001) and fall asleep faster (p <0.001). Also the Brief Infant Sleep Questionnaire scores are significantly reduced: children sleep an extra hour per night (p <0.001), half an hour before going to sleep (p<0.001) than before and during the night awake half the time (p <0.001). Finally, none collateral effects was occurred. Conclusions. The herbal compound of Eschscholtzia californica and Passiflora incarnata (Vagostabil® Junior) can improve significantly the quality of sleep in pediatric patients without contralateral effects.
Show more